Month: September 2026

SaverOne’s 17th granted patent enables its in-vehicle Safety system to self-calibrate and maintain, supporting full accuracy over the life of the vehicle and remote service at fleet scale

Petah Tikvah, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company specializing in radio frequency (RF)-based solutions for the advanced transportation safety, defense and homeland security markets, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new U.S. patent (US 12,742,850 B2) for the sensor fusion-based classification of calibration and maintenance events of its Phone Location Unit (PLU), supporting its detection and prevention of driver distraction. The patent was granted on September 22, 2026.

With this new patent, SaverOne’s IP portfolio includes 23 patents of which 17 have been granted across multiple jurisdictions and six remain pending. SaverOne’s patents cover key markets including the United States, Europe, Israel, China, and the United Kingdom, supporting the Company’s strategic vision for global commercialization.

Mr. Ori Gilboa, CEO of SaverOne, stated, “We are pleased to receive this new U.S. patent, which further strengthens SaverOne’s strong intellectual property portfolio and demonstrates our technological edge. As our systems are deployed across larger commercial fleets, keeping every unit accurate over the life of the vehicle becomes increasingly important. This technology allows our Phone Location Unit to recognize when it needs calibration or maintenance and what type of action is required, supporting our efficient remote service at-scale. Each new patent reinforces the differentiated nature of our technology and the long-term value we are building for our shareholders.”

About SaverOne

SaverOne is a technology company specializing in RF-based solutions for the advanced transportation safety, defense and homeland security markets. SaverOne designs, develops and commercializes OEM and aftermarket technologies that detect, locate and analyze cellphone RF signals using proprietary hardware, software, AI and algorithms.

SaverOne’s first commercial product line is designed to prevent vehicle accidents caused by driver distraction from mobile phone use. Building on the same core RF sensing platform, SaverOne is also developing solutions for vulnerable road user (VRU) detection under limited-visibility and non-line-of-sight conditions, based on the cellphone footprint of pedestrians and other road users.

In 2026, SaverOne expanded the potential applications of its RF sensing technology beyond transportation through its strategic transaction with VisionWave Holdings, Inc. (Nasdaq: VWAV), focused on integrating SaverOne’s RF capabilities into defense, homeland security and critical infrastructure applications.

Learn more at https://saver.one/

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws that are subject to substantial risks and uncertainties. All statements, besides those of historical fact, contained in this press release are forward-looking. Forward-looking statements contained in this press release include but are not limited to, statements regarding SaverOne’s strategic and business plans, technology, relationships, objectives, and expectations for its business, the impact of trends on and interest in its business, intellectual property or product and its future results, operations, and financial performance and condition and may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions. However, not all forward-looking statements contain these words. Forward-looking statements are based on SaverOne’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions about future events that may not prove accurate. Many factors could cause SaverOne’s actual activities or results to differ materially from those anticipated in such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the ability of our technology to substantially improve the safety of drivers; our ability to protect our patented technology from infringement by third parties; SaverOne’s planned level of revenues and capital expenditures and its ability to continue as a going concern; SaverOne’s ability to maintain its listing on the Nasdaq Capital Market; the ability of SaverOne’s technology to substantially improve the safety of drivers; its ability to market and sell its products; its plans to continue to invest in research and development to develop technology for both existing and new products; SaverOne’s intention to advance its technologies and commercialization efforts in Europe and globally; acceptance of its business model by investors; the ability to correctly identify and enter new markets; the impact of competition and new technologies; general market, political and economic conditions in the countries in which SaverOne operates; projected capital expenditures and liquidity; SaverOne’s intention to retain key employees, and its belief that it will maintain good relations with all employees; as well as other risks and uncertainties, including, but not limited to, the risks detailed in SaverOne’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 27, 2026 and in subsequent filings with the SEC. Forward-looking statements in this announcement are made as of this date, and SaverOne undertakes no duty to update such information except as required under applicable law.

International Investor Relations Contact:

Ehud Helft
+1 212 378 8040
saverone@ekgir.com

Will Sangster named Executive Vice President & President of Navico Group; Karly Yuds named Senior Vice President & President of Business Acceleration; Marco Bracalente named Chief Technology Officer. All appointments are effective January 1, 2027

METTAWA, Ill., Sept. 29, 2026 (GLOBE NEWSWIRE) — Following the recently announced CEO and Board Chair transitions, effective January 1, 2027, Brunswick Corporation (NYSE: BC), the world’s leading marine technology company, today announced further appointments that will fill the remaining positions on the Brunswick senior leadership team and that further demonstrate Brunswick’s deep bench of exceptional internal talent and disciplined, systematic talent development process.

Will Sangster is named Executive Vice President and President of Navico Group, filling the role opening when Aine Denari succeeds Dave Foulkes as Brunswick Chief Executive Officer. Karly Yuds is named Senior Vice President and President of Business Acceleration, succeeding Sangster. Marco Bracalente is named Chief Technology Officer also succeeding Denari in this role. All appointments are effective January 1, 2027.

“Brunswick is fortunate to have an outstanding leadership team and a deep bench of senior talent across the enterprise,” said Dave Foulkes, Brunswick Chairman and Chief Executive Officer. “These appointments reflect our meticulous long-term talent and succession planning efforts, led by our Chief Human Resources Officer, Jill Wrobel and our Board and its focus on developing and accelerating young leaders with a consistent track-record of success and the skills, experience, and behaviors to lead the Company into the future. As we prepare for Brunswick’s next chapter, I am confident that Will, Karly, and Marco will continue to advance Brunswick’s strategy, maintain its market momentum and continue to create value for our employees, customers, partners, and shareholders.”

Sangster currently serves as Senior Vice President and President, Business Acceleration, leading Freedom Boat Club and Brunswick’s finance, insurance, extended warranty, and pre-owned boat businesses. He previously served as President of Mercury Marine in Europe, the Middle East, and Africa, and has held international leadership roles across Mercury Marine’s Australia, New Zealand, South Pacific and Asia Pacific businesses during his more than 15 years with Brunswick. In his new role, Sangster will lead Navico Group, Brunswick’s portfolio of industry-leading marine electronics, digital systems, and power management product lines and brands, deploying his extensive experience with international markets and customers, proven commercial leadership, and record of building high-performing teams to further advance the business and deliver its strategic plan and targets.

Yuds currently serves as Vice President of Global Supply Chain and Logistics for Mercury Marine, where she oversees a complex, global supply base supporting Mercury’s multibillion-dollar propulsion and parts and accessories businesses. Since joining Mercury in 2016, she has held roles of increasing responsibility across procurement and supply chain, including Vice President, Procurement and Director, Procurement and Supply Chain, and has played a critical role in strengthening Mercury’s global procurement capabilities, resilience, and efficiency, through extensive use of robust business processes, analytics and AI, while navigating significant supply chain challenges. In her new role, Yuds will lead Business Acceleration, Brunswick’s Fastest growing division focused on expanding boating participation and creating new pathways for consumers to experience life on the water through shared access, certified pre-owned boats, and contemporary financing, insurance, extended warranty, and other related services.

Bracalente will continue to serve as Vice President, Product Development & Engineering for Navico Group and in his new role as Chief Technology Officer will lead Brunswick’s enterprise product technology strategy and advanced development in areas including autonomy, connectivity, software-defined vessels, and physical AI.

“Will and Karly are proven leaders who bring distinct and valuable experience to these roles,” said Aine Denari, Brunswick Executive Vice President, President of Navico Group and Chief Technology Officer, and incoming Chief Executive Officer. “Will’s global commercial background and experience leading growth-oriented businesses will serve Navico Group well as it continues to advance connected, integrated technologies for our customers. Karly’s operational expertise, supply chain leadership, and enterprise mindset are well matched to the next phase of Business Acceleration, particularly as we continue to scale Freedom Boat Club and expand new ways for consumers to participate in boating.”

Denari added, “Marco has played a significant role in advancing our technology capabilities and helping deliver innovative products and experiences for our customers. His deep technical expertise, collaborative leadership style, and passion for innovation make him exceptionally well positioned to lead Brunswick’s technology strategy.”

About Brunswick Corporation:

Brunswick Corporation (NYSE: BC) is a global leader in marine recreation, delivering innovation that transforms experiences on the water and beyond. Its technology-driven solutions are informed by deep consumer insights and guided by the belief that “Next Never Rests™.” Brunswick is home to more than 60 industry-leading brands across marine propulsion (including Mercury Marine), parts and accessories (including Attwood), and marine electronics (including Simrad and Lowrance), as well as boat brands including Boston Whaler, Sea Ray, Bayliner, Lund, and Harris. Headquartered in Mettawa, Illinois, Brunswick has approximately 14,500 employees operating in 26 countries. Learn more at Brunswick.com.

CONTACT: Lee
Gordon —
Chief Communications Officer
M: (904) 860-8848 | O: (847) 735-4003

New transceivers and integrated endpoint family simplify zonal architectures and reduce system complexity for automotive and industrial applications

CHANDLER, Ariz., Sept. 29, 2026 (GLOBE NEWSWIRE) — Microchip Technology (Nasdaq: MCHP) today announces the expansion of its 10BASE-T1S portfolio with the introduction of the LAN8679 and LAN8680 10BASE‑T1S PMD transceivers, alongside the LAN8660X/1X/2X family of endpoints with integrated transceivers. Designed to support next-generation zonal architectures, these solutions deliver flexible, space-efficient connectivity that extends Ethernet to the network edge.

As automotive, industrial and robotics systems evolve toward fully Ethernet-based networks, designers face increasing demands for simplified architectures, reduced wiring complexity and efficient edge node integration. Microchip’s latest 10BASE‑T1S devices address these challenges and are designed to meet AEC-Q100 and ISO 26262 functional safety standards, building on Microchip’s VelocityDRIVE™ portfolio with additional multidrop connectivity solutions featuring a standardized, streamlined interface. 

The LAN8679 transceiver provides a standardized Open Alliance 3‑Pin (OA3P) interface in a compact 8‑pin VDFN package, supporting space-constrained edge nodes, while reducing pin count and design complexity. The LAN8680 builds on these capabilities by integrating System Basis Chip (SBC) features, including power management, system wake/sleep control and watchdog supervision. Both devices are engineered to enhance reliability and safety for demanding environments such as automotive and industrial applications.

“Microchip’s latest 10BASE‑T1S portfolio advances our commitment to enabling scalable, all‑Ethernet network architectures,” said Charlie Forni, corporate vice president of Microchip’s networking and connectivity business unit. “By combining OA3P interface simplicity with integrated endpoint functionality, these devices give designers the flexibility to build efficient, reliable systems while significantly reducing complexity at the edge.”

Complementing these devices, the LAN8660X/1X/2X endpoint family integrates a PMD transceiver into a single-chip Remote Control Protocol (RCP) solution. This approach enables designers to deploy compact, fully integrated edge nodes for applications such as control systems, lighting and audio without the need for external PHY components.

By leveraging 10BASE‑T1S multidrop topology, Microchip’s solutions allow multiple nodes—typically eight or more—to share a single bus line. This reduces wiring weight, lowers system costs and eliminates the need for gateways, making it easier to connect sensors and actuators directly to the network edge.

Microchip’s expanded Single Pair Ethernet portfolio targets a wide range of applications, including automotive zonal architecture, industrial automation, robotics and aerospace and defense systems. The products align with industry trends toward consolidated networks and simplified connectivity frameworks, enabling designers to implement efficient and scalable all-Ethernet architectures. For more information about Microchip’s Single Pair Ethernet solutions, visit the website.
Pricing and Availability

The LAN8679, LAN8680 and LAN8660X/1X/2X are available in limited sampling. To learn more, please contact a Microchip sales representative.

Resources

High-res images available through Flickr or editorial contact (feel free to publish):
·Application image: www.flickr.com/photos/microchiptechnology/55399498402/sizes/l

About Microchip Technology:
Microchip Technology Inc. is a broadline supplier of semiconductors committed to making innovative design easier through total system solutions that address critical challenges at the intersection of emerging technologies and durable end markets. Its easy-to-use development tools and comprehensive product portfolio supports customers throughout the design process, from concept to completion. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support and delivers solutions across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. For more information, visit the Microchip website at www.microchip.com.

Note: The Microchip name and logo and the Microchip logo are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. VelocityDRIVE is a trademark of Microchip Technology Incorporated in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies.

Editorial Contact:

Kim Dutton

kim.dutton@microchip.com

Tokyo, Japan, Sept. 29, 2026 (GLOBE NEWSWIRE) — Tokyo Lifestyle Co., Ltd. (“Tokyo Lifestyle” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in Hong Kong, Japan, North America, Thailand, Vietnam, the United Kingdom and Australia, today announced that on September 10, 2026, its board of directors (the “Board”) approved two equity transactions designed to strengthen the Company’s capital structure. The transactions include a direct cash investment by the Company’s Representative Director and the conversion of outstanding shareholder-related debt into equity. Both issuances are scheduled to close on September 29, 2026.

Pursuant to a cash subscription agreement (the “Cash Subscription Agreement”) entered into between Tokyo Lifestyle and Mr. Kanayama, the Company’s Representative Director and Director (Principal Executive Officer), on September 10, 2026, Mr. Kanayama has agreed to subscribe for 1,396,755 Ordinary Shares of the Company (the “Ordinary Shares”) for an aggregate cash consideration of JPY58,838,000 (approximately US$0.38 million). Payment for the cash subscription (the “Cash Subscription”) is scheduled for September 29, 2026.

Pursuant to a separate subscription agreement (the “DES Subscription Agreement”) entered into with Tokushin G.K. (“Tokushin”), an entity owned by Mr. Kanayama and his family, on the same date, Tokushin has agreed to contribute its JPY510,000,000 (approximately US$3.32 million) loan principal receivable from the Company in exchange for 12,106,893 Ordinary Shares (the “Debt-to-Equity Swap”). The loan principal receivable will be extinguished in full upon completion of the contribution. The Debt-to-Equity Swap is scheduled to close on September 29, 2026.

Upon completion of the Debt-to-Equity Swap, the JPY510,000,000 loan principal will be extinguished in full, reducing the Company’s outstanding debt and associated interest burden. The Company believes that by settling the loan principal through equity rather than cash repayment, the transaction will allow the Company to preserve cash resources for business development and other corporate purposes. Together with the Cash Subscription, the transactions are expected to strengthen the Company’s capital base, optimize its balance sheet and enhance its financial flexibility.

The aggregate consideration for the two issuances is JPY568,838,000, equivalent to approximately US$3.7 million based on the exchange rate of JPY153.74 to US$1.00 used for pricing the transactions. The pricing benchmark was US$0.274 per Ordinary Share, equivalent to US$2.74 per American depositary share (“ADS”), with each ADS representing 10 Ordinary Shares. The number of Ordinary Shares issued in each transaction was rounded down to the nearest whole share. The securities to be issued are Ordinary Shares, rather than ADSs.

As previously disclosed in the Company’s press release dated March 5, 2026, the Company and Tokushin entered into a subordinated loan agreement dated November 27, 2025 (the “Original Loan Agreement”), which was executed by both parties on February 24, 2026 and provided for a loan disbursement date of February 1, 2026. The Original Loan Agreement provided for an unsecured loan of JPY300,000,000 bearing a fixed annual interest rate of 2.0%, with interest payable monthly and principal originally repayable on January 31, 2031.

In connection with the Debt-to-Equity Swap, the Company and Tokushin entered into an amendment to the Original Loan Agreement dated September 10, 2026 (the “Amendment”). The Amendment increases the loan principal amount to JPY510,000,000, provides for an additional advance of JPY210,000,000 on September 10, 2026, and changes the repayment date to September 10, 2026. The Amendment also permits the loan principal receivable to be contributed to the Company in exchange for newly issued shares, with the loan principal to be extinguished upon completion of the contribution. To the extent necessary to implement the Debt-to-Equity Swap, the subordination provisions and restrictions on performance under Article 3 of the Original Loan Agreement do not apply. Except as amended, the Original Loan Agreement remains in effect.

The Board approved the Amendment and the terms of the two share issuances at its meetings on September 10, 2026. Mr. Kanayama did not participate in the deliberations or voting on the relevant matters due to his interest in the transactions. The proposals were unanimously approved by the other directors entitled to vote. The Company’s three corporate auditors also unanimously expressed their opinion that the terms of the share issuances did not constitute a favorable issuance under Japanese law.

On September 10, 2026, the Company published an electronic public notice (the “Public Notice”) in Japan setting forth the approved issuance terms. English translations of the Public Notice, the Amendment, the Cash Subscription Agreement and the DES Subscription Agreement were furnished as exhibits to a Form 6-K filed with the U.S. Securities and Exchange Commission on September 21, 2026.

Mr. Mei Kanayama commented: “These transactions reflect my family’s and my continued commitment to Tokyo Lifestyle. Through the Cash Subscription, I am investing additional personal capital in the Company, while Tokushin is converting its JPY510 million loan principal into equity. We believe these actions will support the Company’s long-term development by strengthening its capital base and improving financial flexibility. We remain focused on disciplined execution and creating long-term value for our shareholders.”

About Tokyo Lifestyle Co., Ltd.

Headquartered in Tokyo, Japan, Tokyo Lifestyle Co., Ltd. (formerly known as Yoshitsu Co., Ltd) is a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys, and other products in Hong Kong, Japan, North America, Thailand, Vietnam, the United Kingdom and Australia. The Company offers various beauty products (including cosmetics, skincare, fragrance, and body care products), health products (including over-the-counter drugs, nutritional supplements, and medical supplies and devices), sundry products (including home goods), collectible cards and trendy toys (including Pokémon cards, BE@RBRICK and other trendy products) and other products (including food and alcoholic beverages). The Company currently sells its products through directly-operated physical stores, through online stores, and to franchise stores and wholesale customers. For more information, please visit the Company’s website at https://www.ystbek.co.jp/irlibrary/.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s annual report and in its other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:
Tokyo Lifestyle Co., Ltd.
Investor Relations Department
Email: ir@ystbek.co.jp

Ascent Investor Relations LLC
Tina Xiao
President
Phone: 1-646-932-7242
Email: investors@ascent-ir.com

LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (“MF”) and anemia on concurrent ruxolitinib therapy.

“The milestone marks another important step forward for the elritercept program,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. “We are grateful to our partner Takeda for their dedication to bringing this important potential new treatment to patients in need.”

Under the terms of the global license agreement with Takeda to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau, which became effective on January 16, 2025, Keros received a $200 million upfront cash payment in February 2025, and is eligible to receive development, commercial and sales milestones with the potential to exceed $1.1 billion. Keros will also be eligible to receive tiered royalties on net sales.

Keros expects to distribute 25% of the net cash proceeds from this milestone payment to its stockholders following receipt of the payment.

About Elritercept

Elritercept is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-ß receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. Elritercept is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with MF.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with MF.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect,” “potential,” “will,” “eligible” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ expectations regarding the progress of the elritercept program; the expected milestone payment under the global license agreement with Takeda; the expected distribution of net proceeds from such milestone payment to Keros’ stockholders; and the other potential milestone and royalty payments under the global license agreement with Takeda. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 3, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
Justin Frantz
jfrantz@kerostx.com 
617-221-6042

New capabilities help B2C and B2B merchants create richer, AI-ready product data at scale and form the foundation of Commerce’s broader agentic commerce solutions

AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) — As AI reshapes how products are discovered and purchased, the quality of a merchant’s product data is becoming a decisive competitive advantage. Commerce (NASDAQ: CMRC), the open commerce ecosystem built to help merchants win as AI reshapes how customers discover and buy, today announced Feedonomics Enrichment and BigCommerce Catalog Enrichment. These new capabilities help B2C and B2B merchants transform their catalogs into richer, AI-ready product intelligence at scale.

The new enrichment capabilities form the cornerstone of Commerce’s agentic commerce solutions, a growing collection of products and capabilities designed to help merchants prepare their product data for agent-powered discovery, connect AI tools securely to their businesses and enable new shopping and store management experiences.

Product data has always been an operational requirement, but in an AI-driven market, it becomes the deciding factor. If an AI answer engine can’t access the relevant information about a product, it won’t surface the product in response to a user’s question. Shoppers and B2B buyers alike are already asking AI apps to compare products, answer questions and, increasingly, complete purchases. Those experiences depend on product data that’s contextually rich and brand-aligned, so buyers are matched with the brands, manufacturers and distributors best suited to them. Traditionally, catalogs have been written for humans browsing a website, not for AI agents parsing and interpreting product data at scale. Enrichment closes that gap by improving the quality and structure of that data. It also gives merchants and their teams a governed way to put AI to work inside their own business.

“AI agents can only answer questions about your products as well as your data allows. Whether you’re a marketer driving AEO or a product leader building shopping agents, better data is the foundation for better agentic experiences,” said Sharon Gee, senior vice president of product for AI at Commerce. “Feedonomics Enrichment and BigCommerce Catalog Enrichment give brands on any platform a data pipeline that lifts performance everywhere agents meet shoppers from Google to OpenAI and on their own sites and agents.”

Commerce’s enrichment solutions turn the product information a brand already has into more robust, consistent data. Both Feedonomics Enrichment and BigCommerce Catalog Enrichment generate product titles, descriptions, feature bullets, FAQs and SEO metadata. They also produce the structured facts, snippets and Q&A fields that generative experiences use to interpret what a product is, who it is for and why it’s a relevant match. Feedonomics Enrichment extends that foundation to the product fields used across marketplace and advertising destinations, while mapping content to a brand’s own taxonomy.

Because the same enriched foundation travels with the data, the effect compounds across four parts of a merchant’s business:

• Reaching customers. Consistent, complete records give shoppers and agents the detail they need to find and match products across storefronts, advertising channels, marketplaces, social platforms and answer engines, so a product is represented the same way, wherever discovery happens.
• Running the storefront. Enrichment removes the need for CSV exports, third-party tools and agency projects that take hours to maintain, so catalog quality stays current without the manual upkeep, with merchants still in control of what goes live.
• Selling products. AI can only recommend what it can understand. Contextual product content lets a conversational experience take a shopper’s question, match it to a specific product and provide a credible reason to choose it.
• Building experiences. Structured, machine-readable product data is what developers build on. It makes a catalog usable by the assistants, storefronts and agent-facing experiences.

Feedonomics Enrichment

Feedonomics Enrichment helps enterprise and multichannel brands transform complex product catalogs into consistent, channel-ready content at scale. Its data model supports storefront, search and answer-engine content across destinations such as Google, Meta, Amazon and eBay, as well as agentic surfaces like Gemini, ChatGPT and CoPilot.

Available through both self-managed and managed-service models, Feedonomics Enrichment enables merchants or their Feedonomics teams to configure and run enrichments through a native self-serve integration. The offering includes a merchant-facing quality scorecard that evaluates accuracy, consistency and brand adherence, with an explainable issue list for anything that may require attention.

A new analytics experience also gives brands visibility into performance signals across onsite traffic and paid media, helping them evaluate how enriched product information performs across the customer journey. An additional conversational reporting agent experience is planned to make those insights easier to explore using natural-language questions.

Feedonomics Enrichment is currently available for English-only product content generation with multi-language capabilities coming soon.

Learn more about Feedonomics Enrichment and request a demo: https://feedonomics.com/product/agentic-commerce/ai-data-enrichment/

BigCommerce Catalog Enrichment

BigCommerce Catalog Enrichment is designed to give merchants a native, self-serve way to enhance product content directly within the BigCommerce control panel. Merchants can select products, provide brand inputs and generate titles, descriptions, feature bullets, FAQs, SEO metadata and structured fields specifically designed to drive greater AEO and GEO performance.

Guided workflows enable merchants to enrich thousands of products without leaving their store’s control panel. Generated content is evaluated using a proprietary quality scorecard focused on accuracy, consistency and adherence to a merchant’s brand voice. Merchants can then review the results and apply enrichments across their entire catalog in a single click, eliminating the need to export catalogs to an outside tool and re-import the results.

“There are four things merchants have to get right in the agentic era: be discoverable by agents, put agents to work running the business, convert inside the conversation and build on open standards so none of it locks you in,” Gee said. “Our agentic commerce solutions do all four, and we deliver them without asking a merchant to hand over their first-party data or their customer relationship to get there.”

Learn more about Commerce’s agentic solutions: https://www.bigcommerce.com/product/agentic-commerce/

About Commerce
Commerce (Nasdaq: CMRC) empowers businesses to innovate, grow, and thrive by providing an open, AI-driven commerce ecosystem. As the parent company of BigCommerce, Feedonomics, and Makeswift, Commerce connects the tools and systems that power growth, enabling businesses to unlock the full potential of their data, deliver seamless and personalized experiences across every channel, and adapt swiftly to an ever-changing market. Trusted by leading businesses like Coldwater Creek, Cole Haan, Dell, Harvey Nichols, King Arthur Baking Co., Mizuno, Pacsun, Perry Ellis, Skechers, SportsShoes and Uplift Desk, Commerce delivers the storefront control, optimized data, and AI-ready tools businesses need to grow, serve diverse buyers, and operate with confidence in an increasingly intelligent, multi-surface world. For more information, visit www.commerce.com or follow us on X and LinkedIn.

BigCommerce®, the Commerce logo, and other brands are the trademarks or registered trademarks of Commerce.com Pty. Ltd. Third-party trademarks and service marks are the property of their respective owner.

Media Contact:
Brad Hem
pr@commerce.com

• Revenues Up 18.7% to $33.4 Million
• Net Income Up 17.4% to $4.5 Million
• Copper Alloy Revenue Up 39%

SAN RAFAEL, BULACAN, PHILIPPINES, Sept. 29, 2026 (GLOBE NEWSWIRE) — One and One Green Technologies, Inc. (Nasdaq: YDDL) (“One and One” or the “Company”), a waste materials and scrap metal recycler that produces copper alloy, aluminum alloy and brass alloy ingots in the Philippines, today reported financial results for the six months ended June 30, 2026.

Revenues rose 18.7% to $33.38 million from $28.13 million, and net income rose 17.4% to $4.49 million from $3.83 million. The increase occurred despite a 10.4% decrease in total material shipped, as the Company reallocated processing capacity to copper alloy ingots. Copper alloy volume rose 29.1%, and copper alloy ingots accounted for 77.0% of total revenue compared with 65.8% a year earlier.

Gross margin narrowed to 21.73% from 25.32%. The decrease reflected the equipment upgrade, during which period aluminum processing was suspended for approximately six weeks of the first half while related costs continued to be incurred, together with higher raw material purchase prices across product categories. Realized price per kilogram sold rose 32.5%, while cost per kilogram sold rose 38.8%.

FINANCIAL SUMMARY

Six months ended June 30	2026		2025		Change
Revenues	$33,380,930		$28,129,714		+18.7%
Gross profit	7,253,731		7,121,544		+1.9%
Gross margin	21.73%		25.32%		(359) bps
Income from operations	4,987,156		5,704,032		(12.6)%
Income before income taxes	6,133,918		4,910,906		+24.9%
Net income	$4,492,677		$3,826,300		+17.4%
Earnings per share, basic and diluted	$0.08		$0.07		+10.9%*

*Change calculated on unrounded earnings per share of $0.0816 and $0.0736.

REVENUE AND PRODUCT MIX
Revenues were $33.38 million, an increase of $5.25 million, or 18.67%, from $28.13 million. Copper alloy ingot revenue rose 38.9% to $25.71 million from $18.51 million on volume growth of 29.10%, reflecting stronger demand across key end markets in the Asia-Pacific region. Aluminum alloy revenue was $6.42 million compared with $8.61 million, primarily reflecting the suspension of aluminum processing from mid-May through the end of the period while the Company upgraded its aluminum processing equipment, together with the reallocation of capacity to copper alloy ingots. Aluminum production resumed in July 2026. Brass alloy ingot revenue rose 25.0% to $1.25 million.

Product category	1H26 revenue	1H26 kg	1H25 revenue	1H25 kg
Copper alloy ingots	25,710,094	2,764,349	18,510,036	2,141,245
Aluminum alloy	6,419,807	2,348,060	8,608,800	3,559,143
Brass alloy ingots	1,251,029	211,200	1,000,960	176,700
Slag	—	—	9,918	65,000
Total	33,380,930	5,323,609	28,129,714	5,942,088

COST OF REVENUE AND GROSS MARGIN
Cost of revenue was $26.13 million, an increase of 24.37% from $21.01 million, notwithstanding a 10.41% decline in total sales quantity. The increase reflected the shift in product mix toward copper alloy ingots, which carry a materially higher unit cost than aluminum alloy, the suspension of aluminum processing during the equipment upgrade, and higher raw material purchase prices across product categories. Gross profit was $7.25 million, up 1.86%. The Company does not use derivative instruments to hedge its exposure to metal prices.

OPERATING INCOME AND NET INCOME
Income from operations was $4.99 million compared with $5.70 million. Income before income taxes rose 24.9% to $6.13 million, and net income rose 17.42% to $4.49 million.

BALANCE SHEET, WORKING CAPITAL, AND LIQUIDITY
As of June 30, 2026, cash and cash equivalents were $2.71 million compared with $957,285 as of December 31, 2025. Total assets were $73.15 million compared with $56.04 million, total liabilities were $16.47 million compared with $14.22 million, and total shareholders’ equity was $56.67 million compared with $41.82 million. Working capital was $43.55 million compared with $28.04 million.

The increase in working capital reflects the deployment of net proceeds from the April 2026 follow-on public offering, together with retained earnings for the period, into inventory and receivables to support the growth of the copper alloy business. Inventories increased to $17.20 million, and accounts receivable increased to $32.75 million. The Company has no interest-bearing debt other than a vehicle financing arrangement with an outstanding balance of $20,346 as of June 30, 2026.

MANAGEMENT COMMENTARY
Caifen (Tina) Yan, Chief Executive Officer and Chairman of One and One, commented, “The first half was about building capacity for our next stage of growth. We upgraded our processing equipment during the period, and a significant portion of the related costs was recognized in these results. Our aluminum line, which was offline for roughly six weeks of the first half during the upgrade, is back in full production, and that investment is now working for us. With the upgraded lines in operation, we expect gross margin and net income to strengthen through the second half, and we are confident in delivering continued growth in both revenue and net income for full-year 2026.”

“We enter the second half with real momentum. Copper alloy revenue grew approximately 39% in the first half as we pointed our capacity at the strongest demand in Asia-Pacific, and we have built our inventory position ahead of second-half orders. Our new metals recovery line, for which we have already procured more than 2,000 tons of raw material, is on track to begin production before year-end and will add a new source of revenue.”

“Our next lever is raw material. Securing long-term supply agreements in Japan and South Korea will give us more control over input costs and margin, and it is where much of my attention goes between now and year-end. At the same time, we are expanding our alloy range and building an international business development team across Europe, the Americas, and Asia to serve manufacturers who want one reliable supplier. Underpinning all of this is our license to import hazardous waste into the Philippines under the Basel framework, a position that becomes more valuable as regulation tightens in our source markets. We believe One and One is well positioned to turn this year’s investments into sustained, profitable growth.”

About One and One Green Technologies, Inc.
One and One Green Technologies, Inc. is a licensed hazardous waste importer and a licensed recycler of non-ferrous metals and industrial materials in the Philippines. One and One transforms electronic waste, scrap metal, and other raw materials into high-value products, including copper alloy ingots and aluminum scraps. With significant permitted annual processing capacity and advanced processing capabilities, One and One provides economical, flexible, and environmentally responsible recycling solutions to manufacturers and industrial clients across domestic and international markets. One and One is strategically positioned to meet the growing demand for sustainable resource management. For more information, please visit our website at www.onepgti.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the Company’s expectations for geographic expansion into Southeast Asia and other international markets; its plans to establish stable raw material sources in Japan and South Korea; its expectations regarding the benefits of its equipment upgrades, gross margin and net income in the second half of 2026, and full-year 2026 growth; the expected timing of production from its new metals recovery line; its intention to recruit an international business development team; and its intention to pursue strategic acquisitions and investments. These statements are identified by words such as “expect,” “anticipate,” “believe,” “intend,” “plan,” “will,” and similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. These factors include, among others, fluctuations in prevailing market prices for copper, aluminum and brass and the Company’s decision not to hedge that exposure; changes in product mix; the Company’s ability to realize the expected operating benefits of its equipment upgrades; the timely commencement of production from its new metals recovery line; the Company’s ability to source adequate volumes of electronic waste and metal scrap on acceptable terms; customer concentration and the collectability of accounts receivable and the loan receivable; the level of inventories carried; political and social instability in the Philippines; inflationary pressures and movements in the Philippine peso against the U.S. dollar; the Company’s ability to maintain and renew its environmental permits and licenses; risks associated with the variable interest entity structure through which the Company conducts its operations; and the additional risks described under “Item 3.D. Risk Factors” in the Company’s annual report on Form 20-F filed with the U.S. Securities and Exchange Commission. Copies are available at www.sec.gov. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investor Relations Contact
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com

(Financial tables follow)
ONE AND ONE GREEN TECHNOLOGIES. INC UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (In U.S. dollar except for share and per share data)
		June 30, 2026 (Unaudited)				December 31, 2025
ASSETS
Current Assets
Cash and cash equivalents		$	2,712,933			$	957,285
Accounts receivable, net			32,745,976				26,634,057
Inventories, net			17,195,077				7,230,581
Advances to suppliers			1,351,811				1,914,972
Loan receivable			1,860,000				2,000,000
Other receivables and current assets			1,102,301				216,042
Total Current Assets			56,968,098				38,952,937
Non-Current Assets
Property, plant and equipment, net			10,167,824				10,284,569
Deferred tax assets			–				109,826
Other non-current assets			200,000				690,135
Operating lease right-of-use assets, net			5,810,975				6,007,527
Total Non-Current Assets			16,178,799				17,092,057
Total Assets			73,146,897				56,044,994
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accounts payable			4,212,075				1,712,220
Due to related parties			202,971				585,193
Taxes payable			8,577,445				7,390,025
Operating lease liabilities – current			–				641,564
Other payables and accrued expenses			427,038				579,744
Total Current Liabilities			13,419,529				10,908,746
Non-Current Liabilities
Deferred tax liabilities			6,540				–
Operating lease liabilities – non-current			3,042,152				3,301,395
Other non-current liabilities			5,984				13,727
Total Non-Current Liabilities			3,054,676				3,315,122
Total Liabilities			16,474,205				14,223,868
Commitments and Contingencies (Note 14)
Shareholders’ Equity
Class A Ordinary Shares, $0.0001 par value; 489,796,040 shares authorized as of June 30, 2026 and December 31, 2025; 45,829,373 and 44,096,040 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively			4,583				4,410
Class B Ordinary Shares, $0.0001 par value; 10,203,960 shares authorized as of June 30, 2026 and December 31, 2025; 10,203,960 and 10,203,960 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively			1,020				1,020
Shares subscription receivable			(5,200	)			(5,200	)
Additional paid-in capital			22,045,669				10,220,329
Retained earnings			38,159,356				33,666,679
Accumulated other comprehensive loss			(3,532,736	)			(2,066,112	)
Total Shareholders’ Equity			56,672,692				41,821,126
Total Liabilities and Shareholders’ Equity		$	73,146,897			$	56,044,994

  

ONE AND ONE GREEN TECHNOLOGIES. INC UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (In U.S. dollar except for share and per share data)
		For the Six months ended June 30,
		2026 (Unaudited)				2025 (Unaudited)
Revenues		$	33,380,930			$	28,129,714
Cost of revenues			26,127,199				21,008,170
Gross profit			7,253,731				7,121,544
Operating expenses:
Selling and marketing expenses			219,295				249,558
General and administrative expenses			2,047,280				1,167,954
Total operating expenses			2,266,575				1,417,512
Income from operations			4,987,156				5,704,032
Other income (expenses):
Interest income			29,114				307
Other income (expenses), net			1,120,518				(790,420	)
Interest expense			(2,870	)			(3,013	)
Total other income (expenses)			1,146,762				(793,126	)
Income before income tax expenses			6,133,918				4,910,906
Income tax expenses			1,641,241				1,084,606
Net income		$	4,492,677			$	3,826,300
Weighted average shares outstanding for Class A and Class B ordinary shares
Basic and diluted			55,056,538				52,000,000
Earnings per share for Class A and Class B ordinary shares
Basic and diluted		$	0.08			$	0.07
Other comprehensive income (loss):
Net income		$	4,492,677			$	3,826,300
Foreign currency translation adjustment, net of tax of nil			(1,466,624	)			703,331
Total comprehensive income		$	3,026,053			$	4,529,631

  

ONE AND ONE GREEN TECHNOLOGIES. INC UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In U.S. dollar except for share and per share data)
		For the Six months ended June 30,
		2026 (Unaudited)				2025 (Unaudited)
Cash flows from operating activities
Net income		$	4,492,677			$	3,826,300
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation of property, plant and equipment			434,996				456,709
Amortization of operating lease right-of-use assets			(50,329	)			79,867
Deferred income tax			114,558				(1,145	)
Amortization of deferred expenses			206,404				–
Changes in assets and liabilities
Accounts receivable			(7,373,982	)			667,809
Inventories			(10,506,363	)			(15,034,423	)
Advances to suppliers			496,473				–
Other receivables and current assets			(1,113,176	)			(327	)
Other non-current assets			477,789				–
Accounts payable			2,631,534				7,149,232
Other payables and accrued expenses			(137,946	)			538,611
Taxes payable			1,525,401				1,079,500
Due to related parties			(372,251	)			(28,714	)
Operating lease liabilities			(757,286	)			(465,891	)
Net cash used in operating activities			(9,931,501	)			(1,732,472	)
Cash flows from investing activities
Purchase of property, plant and equipment			(746,169	)			–
Collection of loan receivable			140,000				–
Net cash used in investing activities			(606,169	)			–
Cash flows from financing activities
Payment of deferred offering costs			–				(25,516	)
Net proceeds from share and warrants issuance			11,825,513				–
Principal payments on financed amount for purchase of vehicle			(7,353	)			–
Net cash provided by (used in) financing activities			11,818,160				(25,516	)
Effect of exchange rate changes on cash and cash equivalents			475,158				32,921
Net (decrease) increase of cash and cash equivalents			1,755,648				(1,725,067	)
Cash and cash equivalents – beginning of the year			957,285				1,847,634
Cash and cash equivalents – end of the year		$	2,712,933			$	122,567
Supplementary cash flow information:
Interest paid		$	2,870			$	3,013
Income taxes paid		$	1,252			$	978

# # #

NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place September 29 to October 2, 2026 in Orlando, Florida.

“Despite important advances in the treatment of generalized myasthenia gravis, there remains a need for therapies that can provide consistent disease control while reducing the treatment burden for patients,” said Tuan Vu, MD, Professor of Neurology at the University of South Florida Morsani College of Medicine. “The sustained efficacy results and continued favorable safety profile observed for claseprubart in the Phase 2 MaGic open-label extension are encouraging and support its continued development as a potential differentiated treatment option for patients with gMG.”

“For people living with CIDP, functional impairment can have a substantial impact on everyday life, underscoring the need for new treatment options beyond IVIG,” said Richard Lewis, MD, Professor of Neurology at Cedars-Sinai. “The 75% response rate observed in the interim responder analysis of the first 40 participants completing unblinded Part A of the Phase 3 CAPTIVATE trial is encouraging, particularly given the consistent and clinically meaningful improvements demonstrated across multiple measures of function and disability in a broad patient population with varied prior treatment experience. These findings highlight the potential for claseprubart to offer a new approach to the treatment of CIDP.”

Oral Presentation

October 1, 2026, 1:21-1:29 p.m. ET
Industry-Supported Research Highlights | Presentation #149 
CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 
Presented by Richard Lewis, MD 

Poster Presentations

September 29, 2026, 2:30-3:30 p.m. ET
MGFA Scientific Session | Poster #5 
Sustained Safety and Efficacy Profile of Active C1s Inhibitor Claseprubart in Patients with Generalized Myasthenia Gravis 
Presented by Tuan Vu, MD 

September 30, 2026, 6:15-6:45 p.m. ET and October 1, 2026, 2:45-3:15 p.m. ET
Poster #186 
Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 
Presented by Said Beydoun, MD 

September 30, 2026, 6:15-6:45 p.m. ET and October 1, 2026, 2:45-3:15 p.m. ET
Poster #320 
Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 
Presented by Tuan Vu, MD 

September 30, 2026, 6:15-6:45 p.m. ET and October 1, 2026, 2:45-3:15 p.m. ET
Poster #149 
CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 
Presented by Jeffrey Allen, MD

Presentations will be available in the Scientific Publications section of the Dianthus Therapeutics website.

About Claseprubart (DNTH103)
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. As the classical pathway plays a significant role in disease pathology, claseprubart has the potential to be a best-in-disease pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Claseprubart was granted Orphan Drug Designation by the FDA for the treatment of Myasthenia Gravis in May 2026.

Dianthus is building a neuromuscular franchise with claseprubart and expects to report top-line data from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in December ’26, to provide an update on timing of top-line data from Part B of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy by YE’26, and to report top-line results from the Phase 3 EMERGE trial in generalized Myasthenia Gravis in 2H’28.

Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and prospects, including statements regarding the expectations or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to claseprubart, and any developments or results in connection therewith, including the target product profile and administration of claseprubart; the anticipated timing of the initiation and results from those studies and trials; expectations regarding the clinical trial designs or indications; expectations regarding the time period over which the Company’s capital resources are expected to be sufficient to fund its anticipated operations; and expectations regarding market size, patient population size, and potential market opportunities, in particular with respect to claseprubart. Claseprubart is an investigational agent that is not approved in any indication in any jurisdiction worldwide. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the preliminary interim analysis based on a limited number of patients from the Part A open label portion of the claseprubart CAPTIVATE study in patients with CIDP may not be predictive of the results or success of the remaining patients treated in Part A or patients treated in Part B of the CAPTIVATE study, that the development of claseprubart may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company’s compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026

TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that the first patient has been enrolled and dosed in the Company’s Phase 1 pharmacokinetic (PK) trial of NS003, its proprietary intranasal powder formulation of ondansetron being developed for chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV).

In a recent pre-clinical study comparing NS003 to the intravenous (“IV”) formulation of ondansetron in animals, results showed that NS003 had a PK profile comparable to the IV formulation, with similar time to maximum concentration (Tmax) and area under the curve (AUC) results. In a separate safety study, NS003 demonstrated a favorable safety profile at four times the test dose, with no adverse effects observed. The current Phase 1 PK study will assess the pharmacokinetic and safety profile of NS003 in human patients for the first time.

“Enrolling and dosing our first patient in this Phase 1 study of NS003 demonstrates our ability to execute on previous guidance, and we are very pleased to achieve this milestone,” said Brendan O’Grady, Chief Executive Officer of Nasus. “Ondansetron remains one of the most widely prescribed anti-emetics, with significant usage of the IV formulation in the hospital setting. A fast-onset, needle-free option could offer real value for patients who aren’t fully controlled on oral therapy. Intranasal administration of NS003 has the potential to address these unmet needs by offering a convenient, fast-onset alternative that may reduce avoidable clinic visits. We look forward to announcing topline PK data from this study before year-end, along with the initiation of our pivotal NS002 study for anaphylaxis, also targeted for the fourth quarter.”

Ondansetron is one of the most widely used therapies for chemotherapy-induced nausea and vomiting. In 2023, more than 12 million prescriptions for orally administered were dispensed to over 6 million patients. Zofran^®(ondansetron) peak sales exceeded $1.5 billion.

About Nasus Pharma

Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward-looking statements in this press release when it discusses: the planned initiation and timing of a first-in-human PK study and Phase 1 trial for NS003, the timing of the NS002 pivotal study, expected clinical and development milestones, and the expansion of the Company’s product portfolio. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Corporate Contact
Nasus Pharma Ltd. Israel
info@nasuspharma.com

Investors Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

Naples, Italy and Hamilton, Bermuda, Sept. 29, 2026 (GLOBE NEWSWIRE) — The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games as well as ownership and growth of its Italian professional football club Savoia 1908 FC (“Savoia” or the “Club”), today announced that Savoia has been wearing Nike since the first match of the 2026/2027 season, under an agreement with GTeamGWear, one of the leading Italian distributors of prestigious sports brands operating at a European level, including Nike, that runs for four seasons, through the 2029/2030 campaign.

An Important Sponsorship

The agreement marks a significant step for Savoia as the Club continues to progress in Italian professional football, bringing one of the most recognized names in sport to its kit for the first time. Since the season’s opening match, Savoia’s players have taken the field in Nike-branded training and match apparel, aligning the Club’s on-pitch identity with a global sporting brand as it builds toward its long-term ambitions.

Delivered Through GTeamGWear

The sponsorship has been formalized through GTeamGWear, Nike’s authorized distributor for the agreement, and one of the principal Italian distributors operating at the European level in the sports sector. GTeamGWear works with prestigious sports brands, including Nike, to bring their products to clubs and organizations across Europe, and will serve as Savoia’s sponsor in delivering Nike apparel and equipment for the four-season term of the agreement.

A Milestone for the Club’s Growing Identity

For Savoia, the Nike sponsorship represents another milestone in the Club’s development since its return to professional football, complementing its sporting progress on the pitch with a strengthened brand presence off it. The Club considers the agreement an important step in building a modern, professional identity befitting its history and its ambitions for the years ahead.

One of the Savoia 1908 26-27 kits.  

A Brand on the Rise

“This agreement represents tangible evidence of the strength, prestige, and growing relevance of the Savoia brand. Today, the value of our brand is comparable, in terms of importance and potential, to that of clubs competing in Serie A. This is not simply our own assessment, but a conclusion supported and certified by a consultancy conducted by Deloitte in May 2026. Seeing the historic Savoia crest alongside Nike, one of the most prestigious and internationally recognized brands in the world of sport, is a source of great pride for us. It is also confirmation of the growth path we are pursuing and of the stature that Savoia is progressively reclaiming.”

–  General Manager and Chief Operating Officer of Savoia, Nazario Matachione.

About The RoyaLand Company Ltd.

The RoyaLand Company Ltd. is a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land as well as mobile and other games, and ownership and growth of its Italian professional football club Savoia 1908 FC. The Company is actively focused on developing what it believes to be a novel, interactive and immersive game based on a player-empowered design. This game is expected to feature proprietary digital avatars and provide opportunities to players to earn in-game reward currency, build virtual land, and own their online assets while enhancing all of these features with premium incremental in-game content. Bridging the virtual video game world and terrestrial soccer, Savoia 1908 FC has also completed a tournament season for its eSports team competing in EA Sports FC™ online matches.

TheRoyal.Land and the management and development of Savoia 1908 FC are being conducted in collaboration with the Company’s founder and CEO Prince Emanuele Filiberto di Savoia — the grandson of the last King of Italy — as well as seven other royal families and families with legal, hereditary or historically based claims to royal positions in Russia, Albania, France, Bulgaria, Yugoslavia, Lesotho (Africa), and Mecklenburg (Germany). TheRoyal.Land is intended to integrate these families’ first-hand historical perspectives to deliver an authentic and unique past-meets-future entertainment experience.

CONTACT:
investors@theroyal.land
www.TheRoyal.Land

Attachment

• One of the Savoia 1908 26-27 kits.